Gilead Sciences (GILD) R&D In Process (2019 - 2025)
Gilead Sciences (GILD) has disclosed R&D In Process for 7 consecutive years, with $539.0 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, R&D In Process rose 5000.0% year-over-year to $539.0 million, compared with a TTM value of $1.0 billion through Dec 2025, down 76.9%, and an annual FY2025 reading of $1.0 billion, down 78.04% over the prior year.
- R&D In Process was $539.0 million for Q4 2025 at Gilead Sciences, up from $170.0 million in the prior quarter.
- Across five years, R&D In Process topped out at $3.9 billion in Q1 2024 and bottomed at -$11.0 million in Q4 2024.
- Average R&D In Process over 5 years is $393.3 million, with a median of $164.0 million recorded in 2022.
- The sharpest move saw R&D In Process tumbled 110.89% in 2024, then skyrocketed 5000.0% in 2025.
- Year by year, R&D In Process stood at $669.0 million in 2021, then crashed by 76.38% to $158.0 million in 2022, then plummeted by 36.08% to $101.0 million in 2023, then crashed by 110.89% to -$11.0 million in 2024, then surged by 5000.0% to $539.0 million in 2025.
- Business Quant data shows R&D In Process for GILD at $539.0 million in Q4 2025, $170.0 million in Q3 2025, and $62.0 million in Q2 2025.